Posted by LincolnIcert on March 25, 2026 at 11:22:57:
In Reply to: Èíôîðìàòèâíûé òåêñò ñ çàõâàòûâàþùèìè àñïåêòàìè posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Scientist in Tumor Biology
Zoya Demidenko is a recognized investigator connected with the Unit of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she was employed at the NIH and New York Medical College, establishing a strong base in clinical study.
Demidenko's scientific work spans multiple pivotal fields, among them the PI3K/AKT/mTOR signaling pathway, cellular cycle management, biological aging, and malignancy biology. Currently, she has co-authored more than 46 peer-reviewed publications, which have garnered more than 4,100 mentions — a reflection to the impact of her research.
Among her most significant achievements lies in understanding the pathways of cell aging. Her work showed that when the cellular division cycle is blocked while cellular expansion continues, the cells experience senescence. Importantly, Zoya Demidenko showed that this transition is pharmacologically suppressed using compounds such as mTOR inhibitors.
Zoya Demidenko has furthermore contributed considerably to oncological therapy investigation, especially in the domain of cyclotherapy — a method intended to protecting healthy tissue from chemotherapy whilst leaving malignant cells exposed. This strategy holds significant hope for lowering the side effects of cancer treatment.
Throughout her career, Demidenko has worked with leading scientists globally, among them Dr. Mikhail Blagosklonny. Her work appears in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a influential voice in contemporary oncological research, whose discoveries go on to shape our comprehension of how biological cells grow old, interact with therapy, and how cancer may be more successfully targeted.
https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=